Microbiome-as-a-Drug
A global FMT service company — redefining medicine with Microbiome × AI.
The thesis
Microbiome-as-a-Drug: engineering the microbiome into reproducible medicine.
We treat the gut microbiome as a programmable drug class — built on a 300+ strain library, industrialized FMT 3.0, and AI-native discovery — and direct it at two high-unmet-need tracks: CNS (depression & mood disorders) and oncology (ICI sensitization & anti-metastasis).
300+
Reserved functional strains
5+
World medical records
10,000+
FMT & assays performed
Depression & Mood Disorders
Rapid-acting microbiome interventions targeting the gut–brain axis.
View pipeline →ICI Sensitization & Anti-metastasis
Microbiome modulation to potentiate immune-checkpoint therapy.
View pipeline →Evidence
Outcomes the world has noticed
Onco · Stage IVB pMMR/MSS colorectal cancer
Complete remission achieved — first reported case globally.
Source: Cureus, 2024
CNS · Insomnia / sleep disturbance with anxiety
Improved sleep quality reported across the case series; mechanism discussed via serotonin, metabolites and immune-inflammatory pathways.
Source: Internal case series, 2023
Two brands · one company
aFMT and SereneSwift, both operated by JCY Bio
The clinical platform and the consumer expression of the same microbiome science — one to hospital, one to daily life.
Clinical · To Hospital
aFMT
Industrialized FMT 3.0 for hospitals and research partners.
Explore aFMT →Consumer · Gut-Brain
SereneSwift
Medical-grade gut-brain probiotics for everyday emotional balance.
Explore SereneSwift →Backed by clinical & institutional partners
Built with hospitals, state labs, and industry
- Beijing Anding Hospital
- Wuhan Union Hospital
- Shenzhen Children's Hospital
- SIAT, Chinese Academy of Sciences
- Shenzhen Bay Laboratory
- Pingshan Biomedical Translation Center
- Shandong University Second Hospital
- Chinese Society for Microbiology
- Sinopharm
- CMG Life (Zhao Shang Ren He)
- Foresea Life Insurance